Etzer Darout
Stock Analyst at Barclays
(4.61)
# 252
Out of 5,182 analysts
183
Total ratings
53.64%
Success rate
32.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Maintains: Overweight | $79 → $63 | $70.29 | -10.37% | 6 | Apr 22, 2026 | |
| TRAX First Tracks Biotherapeutics | Initiates: Overweight | $40 | $17.76 | +125.23% | 1 | Apr 22, 2026 | |
| MGNX MacroGenics | Maintains: Overweight | $4 → $6 | $3.10 | +93.55% | 12 | Apr 20, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $224 → $225 | $201.27 | +11.79% | 2 | Apr 20, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $44 → $45 | - | - | 7 | Apr 20, 2026 | |
| TVRD Tvardi Therapeutics | Downgrades: Underweight | $4 → $3 | $3.04 | -1.32% | 3 | Apr 20, 2026 | |
| JANX Janux Therapeutics | Downgrades: Underweight | $29 → $14 | $15.29 | -8.44% | 4 | Apr 20, 2026 | |
| CLDX Celldex Therapeutics | Upgrades: Overweight | $24 → $45 | $34.49 | +30.47% | 4 | Apr 20, 2026 | |
| RLAY Relay Therapeutics | Maintains: Overweight | $17 → $21 | $14.90 | +40.94% | 1 | Apr 8, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Overweight | $50 → $78 | $80.72 | -3.37% | 3 | Apr 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $53 | $52.95 | +0.09% | 12 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $142 → $148 | $112.00 | +32.14% | 2 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $113 → $119 | $99.46 | +19.65% | 7 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $16 | $4.21 | +280.05% | 15 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $143 → $128 | $101.35 | +26.30% | 5 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $70 | $46.34 | +51.06% | 10 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $7 | $2.90 | +141.38% | 7 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $27 | $12.95 | +108.49% | 9 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $10.77 | +178.55% | 1 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $11 | $3.45 | +218.84% | 3 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $117 | $95.86 | +22.05% | 3 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $119 → $133 | - | - | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $28 | $15.89 | +76.21% | 2 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $10.48 | +71.76% | 7 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $18 | $22.09 | -18.52% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $35 | $21.03 | +66.43% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $28 | $9.06 | +209.05% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $54.05 | +131.27% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | - | - | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $5.30 | -43.40% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $16.63 | +110.53% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $0.90 | +6,900.00% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.86 | +1,353.88% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $104.75 | +27.92% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $26.48 | +81.27% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $143.19 | -16.20% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.29 | +365.12% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $187.30 | -56.22% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | - | - | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $313.28 | -45.74% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $92.48 | -58.91% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $4.17 | +1,147.00% | 1 | Mar 28, 2018 |
AnaptysBio
Apr 22, 2026
Maintains: Overweight
Price Target: $79 → $63
Current: $70.29
Upside: -10.37%
First Tracks Biotherapeutics
Apr 22, 2026
Initiates: Overweight
Price Target: $40
Current: $17.76
Upside: +125.23%
MacroGenics
Apr 20, 2026
Maintains: Overweight
Price Target: $4 → $6
Current: $3.10
Upside: +93.55%
Jazz Pharmaceuticals
Apr 20, 2026
Maintains: Overweight
Price Target: $224 → $225
Current: $201.27
Upside: +11.79%
Exelixis
Apr 20, 2026
Maintains: Equal-Weight
Price Target: $44 → $45
Current: -
Upside: -
Tvardi Therapeutics
Apr 20, 2026
Downgrades: Underweight
Price Target: $4 → $3
Current: $3.04
Upside: -1.32%
Janux Therapeutics
Apr 20, 2026
Downgrades: Underweight
Price Target: $29 → $14
Current: $15.29
Upside: -8.44%
Celldex Therapeutics
Apr 20, 2026
Upgrades: Overweight
Price Target: $24 → $45
Current: $34.49
Upside: +30.47%
Relay Therapeutics
Apr 8, 2026
Maintains: Overweight
Price Target: $17 → $21
Current: $14.90
Upside: +40.94%
Oruka Therapeutics
Apr 7, 2026
Maintains: Overweight
Price Target: $50 → $78
Current: $80.72
Upside: -3.37%
Mar 30, 2026
Downgrades: Equal-Weight
Price Target: $56 → $53
Current: $52.95
Upside: +0.09%
Mar 24, 2026
Maintains: Overweight
Price Target: $142 → $148
Current: $112.00
Upside: +32.14%
Mar 19, 2026
Maintains: Overweight
Price Target: $113 → $119
Current: $99.46
Upside: +19.65%
Mar 19, 2026
Maintains: Overweight
Price Target: $10 → $16
Current: $4.21
Upside: +280.05%
Mar 11, 2026
Maintains: Outperform
Price Target: $143 → $128
Current: $101.35
Upside: +26.30%
Mar 4, 2026
Maintains: Outperform
Price Target: $50 → $70
Current: $46.34
Upside: +51.06%
Feb 27, 2026
Maintains: Overweight
Price Target: $5 → $7
Current: $2.90
Upside: +141.38%
Feb 26, 2026
Maintains: Overweight
Price Target: $26 → $27
Current: $12.95
Upside: +108.49%
Feb 25, 2026
Maintains: Overweight
Price Target: $26 → $30
Current: $10.77
Upside: +178.55%
Feb 25, 2026
Maintains: Overweight
Price Target: $10 → $11
Current: $3.45
Upside: +218.84%
Feb 18, 2026
Maintains: Overweight
Price Target: $116 → $117
Current: $95.86
Upside: +22.05%
Jan 28, 2026
Maintains: Overweight
Price Target: $119 → $133
Current: -
Upside: -
Jan 21, 2026
Maintains: Overweight
Price Target: $16 → $28
Current: $15.89
Upside: +76.21%
Dec 17, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $10.48
Upside: +71.76%
Dec 17, 2025
Upgrades: Equal-Weight
Price Target: $16 → $18
Current: $22.09
Upside: -18.52%
Nov 24, 2025
Maintains: Overweight
Price Target: $22 → $35
Current: $21.03
Upside: +66.43%
Nov 24, 2025
Maintains: Overweight
Price Target: $11 → $28
Current: $9.06
Upside: +209.05%
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $54.05
Upside: +131.27%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: -
Upside: -
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $5.30
Upside: -43.40%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $16.63
Upside: +110.53%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $0.90
Upside: +6,900.00%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.86
Upside: +1,353.88%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $104.75
Upside: +27.92%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $26.48
Upside: +81.27%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $143.19
Upside: -16.20%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.29
Upside: +365.12%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $187.30
Upside: -56.22%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: -
Upside: -
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $313.28
Upside: -45.74%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $92.48
Upside: -58.91%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $4.17
Upside: +1,147.00%